Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS

 Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS

Novartis Reports Results of Kesimpta (ofatumumab) in P- III ASCLEPIOS Trials for Newly Diagnosed Patients with RMS

Shots:

  • The company reported new post hoc data from the P- III ASCLEPIOS trials assessing Kesimpta (ofatumumab) vs teriflunomide in a subgroup of newly diagnosed, treatment-naïve patients with RMS
  • The results showed a 60% reduction in the risk of disability progression independent of relapse activity @3 and 6 mos., thus supporting Kesimpta as a 1L treatment option for adults with RMS. The data is presented at AAN2021
  • Emerging OLE study data from the ALITHIOS trial showed that Kesimpta precisely delivered through SC administration, mean serum IgM/IgG levels remained within the reference ranges over a 3yrs. period to Dec 2020

Click here to­ read full press release/ article | Ref: Novartis | Image: BioProcess International

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post